“…The first, the individual test approach, assesses longitudinal outcomes either independently or jointly to determine treatment effects for each outcome, followed by multiplicity adjustment. Analytical techniques include parametric methods such as univariate or multivariate GEE and linear mixed models (LMMs), as well as nonparametric methods such as univariate or multivariate functional mixed models (FMMs) (Zhu and others , 2019) and various rank-based tests (Akritas and Brunner, 1997; Konietschke and others , 2010; Brunner and others , 2017; Zhuang and others , 2018; Umlauft and others , 2019; Rubarth and others , 2022 a , b ). Multiplicity adjustment may employ co-primary endpoint strategy, requiring significance across all endpoints for treatment efficacy assertion, adopted in studies such as Semagacestat (Doody and others , 2013), EXPEDITION (Doody and others , 2014), LMTM (Gauthier and others , 2016), and ADMET 2 (Mintzer and others , 2021), or multiple endpoint strategy, requiring at least one significant outcome after multiple comparison corrections (e.g., Bonferroni, Holm, or Hochberg procedures, and fixed-sequence methods) per FDA guidelines (GUIDANCE, 2022).…”